乳腺癌原发灶及淋巴结转移灶中P-gp、GST-π、TopoⅡ的表达及临床意义

doi:10.3971/j.issn.1000-8578.1837

乳腺癌原发灶及淋巴结转移灶中P-gp、GST-π、TopoⅡ的表达及临床意义

Expression and Clinical Significance of P-gp、GST-π and TopoⅡin Breast Cancer and Their Lymph-node Metastasis Tumors

摘要

摘要: 目的探讨乳腺癌原发灶和淋巴结转移灶中P-gp、GST-π、TopoⅡ的表达及相关性。方法选择2005年1～12月所有在我科行手术治疗的乳腺癌患者70例，其中有腋下淋巴结转移的36例，无腋下淋巴结转移的34例，用免疫组化SP法检测原发灶和淋巴结转移灶P-gp、GST-π、TopoⅡ的表达。结果（1）有腋下淋巴结转移的乳腺癌中P-gp、GST-π的表达高于无腋下淋巴结转移的乳腺癌（P=0．043、P=0．012），TopoⅡ的表达两者间差异无统计学意义。（2）乳腺癌原发灶和淋巴结转移灶的GST-π、TopoⅡ表达有相关性（P=0．001、P=0．01），P-gp的表达无相关性。结论（1）P-gp、GST-π高表达与腋下淋巴结转移显著相关。（2）乳腺癌原发灶与淋巴结转移灶的耐药性不尽一致。

Abstract: Objective 　To investigate the protein expressions and relationship of P2gp, GST2π and Topo Ⅱin breast cancer and their lymph2node metastasis tumor. Methods 　High sensitive SP immunohistochemi2 cal method was used to detect the protein expressions of P2gp, GST2πand Topo Ⅱin 70 breast cancers and their lymph2node metastasis tumors (36 with lymphatic metastasis) . Results 　(1) The expressions of P2 gp, GST2πin breast cancers with lymphatic metastasis was higher than those without lymphatic metasta2 sis ( P = 0. 043, P = 0. 012), but the expression of Topo Ⅱ had no difference between the two groups. (2) The expressions of GST2π、To Po Ⅱwere significantly associated with lymphatic metastasis ( P = 0. 001, P = 0. 01) . However, the expression of P2gp was not associated with lymphatic metastasis. Conclusion 　 (1) There was a significant relationship between the higher expression of P2gp, GST2π and the axillary lymph node involvement . (2) The drug2resistance of breast cancers was not as same as their lymph2node metastatic tumors.

HTML全文

参考文献(0)

施引文献

资源附件(0)